Startups

This JHU startup is working on a treatment to prevent Alzheimer’s

AgeneBio received a $7 million grant from the National Institutes of Health to begin a new round of drug trials.

The hands of an Alzheimer's patient. (Photo by Flickr user Ann, used under a Creative Commons license)

A Johns Hopkins startup received a federal grant to enter trials of its treatment for a brain disease that often precedes Alzheimer’s disease.
AgeneBio and Johns Hopkins received a five-year grant from the National Institutes of Health that is projected to total $7.2 million for Phase 3 trials of the therapeutic, called AGB101. If successful, the drug could be the first therapeutic to prevent or delay Alzheimer’s by curing a brain condition that is typically a precursor to the debilitating elderly disorder.
The treatment focuses on a disease known as aMCI. It’s been identified as the earliest point to diagnose a pre-dementia state, and often develops into full-blown Alzheimer’s within a few years. About 5.2 million Americans suffer from the disease.


The therapeutic, which is a low-dose version of a drug used to treat epilepsy, treats overactivity in the hippocampus portion of the brain that is associated with aMCI.
A Phase 2 trial restored brain function and memory in patients. Phase 3 trials, which could last up to two years, are projected to start early next year. That final phase of trials before the company submits to the FDA will involve hundreds of patients.
The treatment grew out of research by Hopkins neuroscientist Michela Gallagher, who founded AgeneBio. The company’s offices are in in Johns Hopkins’ Eastern campus on 33rd Street in Waverly.

Companies: Johns Hopkins University
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Donate to the Journalism Fund

Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.

Trending

Techstars announces AI Health accelerator will stay in Baltimore, with more cash for startups

This Week in Jobs: Kick off "hot labor summer" with these 20 tech career opportunities

Equitech Tuesday ended after 200 meetups. Now, organizers want Baltimore’s input on what’s next.

Technically Media